Abstract: All five ELISA kits manifested similar avidity, which were demonstrated by the slope of the curves, for the sT118M mutant, and sT118M-rtM204I (sT118M-sI195M) and sT118M-rtM204V (sT118M-sW196S) double mutants, suggesting that drug-resistant YMDD mutants caused negligible losses in the antigenicity of immune-escaped
Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran).
PMID: 24064642
2013
Indian journal of medical microbiology
Abstract: Of these, 3 (6.6%) patients had primary resistance mutation (rtM204I, rtA181T and rtA181S) and 20 (44.4%) patients had secondary resistance mutations.
Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.
Abstract: Among LAM/LdT based therapies, HBV rtM204I was significantly associated with HBV rtL80I/V mutations [rtM204I+rtL80I/V (50.0%, 32/64) vs. rtM204V+rtL80I/V (27.3%,9/33), P=0.032]
Abstract: while the HBV rtM204V mutations was significantly associated with HBV rtL180M mutations [rtM204V+rt
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
PMID: 24175847
2013
Asian Pacific journal of cancer prevention
Abstract: Eight of the 17 samples (19.5%) having rtM204V/I/A missense transition and/or transversion point mutations and resistance to lamivudin.
Abstract: The current results provide evidence that rtL180M and rtM204V/I/A mutations of HBV-DNA may be associated with a poor antiviral response and HBV chronicity during conventional therapy in Turkish patients.
Substitution rtq267h of hepatitis B virus increases the weight of replication and Lamivudine resistance.
Result: It follows that rtQ267H could not only reduce the anti-HBV effect of LMV, but also enhance HBV replication which was attenuated by LMV resistant mutation, such as rtM204V/I.
Result: Mutations rtM204V/I weaken HBV replication, while rtL180M could restore the impaired replication capacity, in accordance with previous report.
Result: The results indicated that rtL180M and/or rtM204V/I and/or rtQ267H had no influence on HBsAg and
Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations.
Abstract: Four months after chemotherapy, despite ongoing LAM of 7-month duration with confirmed adherence, severe asymptomatic hepatitis was noted during routine monitoring with ALT 1019 IU/L, HBeAg negative, HBV DNA 1.43E7 IU/mL, and genotyping confirmed L80I and M204I mutations.
Conclusion: HBeAg remained negative, and genotyping with the INNO-LIPA assay confirmed L80I and M204I mutations, conferring lamivudine resistance.
Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi.
PMID: 22001270
2012
The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: The rtS117F substitution served as a compensatory mutation for rtM204I.
Abstract: Emergence of the rtS117F mutation in lamivudine-resistant patients carrying rtM204I was associated with increased hepatitis activities.
Abstract: Emergence of the rtS117F mutation was associated with an increase in hepatitis activity, whereas prior existence of the rtN124D mutation was associated with decompensated liver function upon development of the PMID: 22078148
2012
Journal of clinical virology
Abstract: RESULTS: Dominance of a clone carrying L80LV, L91I, M204I, S219A, N238D, Y245H changes was detected in the last serum sample of the patient just before his death.
The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment.
Abstract: CONCLUSION: Biochemical response at 12 months from baseline was better in patients with a rtM204I mutation than rtM204V+ rtM204I/V mutations.
Abstract: In addition, early treatment failure was more common in patients with rtM204V+ rtM204I/V mutations than a rtM204I mutation.
Abstract: RESULTS: The baseline tyrosine-methionine-aspartate-aspartate (YMDD) mutation patterns were as follows: rtM204
Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Abstract: Clinical and immunologic outcomes in the context of HBV genotypes as well as the emergence of HBV DNA mutations conferring lamivudine resistance (rtM204I/V) were determined.
HBV mutation literature information.
PMID: 
2013
Virology journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT